CD40 is a costimulatory protein found on antigen-presenting cells (APCs) and is required for their activation. The binding of CD154 (CD40L) on T cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.
Similar to the endogenous CD40 ligand (CD40L or CD154), CD40 agonistic antibody LVGN7409 binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Evidence to date suggests that CD40 activation is a critical and nonredundant mechanism to convert so-called cold tumors to hot ones (with prominent tumor infiltration of T cells), sensitizing them to checkpoint inhibition.
Based on different expression profile and anti-tumor activity mechanism between CD40 and other T-cell activating drugs, anti-CD40 antibody is an excellent candidate for combination therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies etc.
For more scientific rationale, please visit CD40 and xLinkAbTM.
We are very proud to announce the first-in-human (FIH) dosing of LVGN7409 (CD40 agonist) on Jan 26, 2021 （NCT04635995）
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: firstname.lastname@example.org or send us a message